Headquartered in Los Angeles, CA Fiscal year ends December NASDAQ: RDNT radnet.com
RadNet, Inc. (NASDAQ: RDNT) operates a network of owned and/or operated freestanding, fixed-site outpatient diagnostic imaging centers in the United States. Its imaging center markets are Arizona, California, Delaware, Florida, Idaho, Indiana, Maryland, New Jersey, New York, Texas and Virginia.
The centers provide:
- Advanced imaging: MRI, CT and PET/CT, which made up 30.6% of procedures in Q3 2026
- Routine imaging: ultrasound, mammography, X-ray and nuclear medicine
Revenue comes from service fees paid mainly by commercial insurers and Medicare, plus capitation arrangements. RadNet increasingly expands through joint ventures with health systems and tuck-in acquisitions.
Through its Digital Health segment, marketed under the DeepHealth brand, RadNet sells radiology information technology and artificial intelligence solutions globally, including the DeepHealth Cloud OS and generative AI tools. It also provides teleradiology professional services to the diagnostic imaging industry.
RadNet has a pending acquisition of ONRAD. Including contracted radiologists, it has over 12,000 team members. Updated
RadNet raised full-year guidance for the third straight quarter, lifting Imaging Center adjusted EBITDA to $350 million to $363 million. Revenue came in just shy of missing expectations, while the earnings beat and a pending ONRAD deal drawing stronger than expected partner interest carry the story.
RadNet, Inc. (NASDAQ: RDNT) operates a network of owned and/or operated freestanding, fixed-site outpatient diagnostic imaging centers in the United States. Its imaging center markets are Arizona, California, Delaware, Florida, Idaho, Indiana, Maryland, New Jersey, New York, Texas and Virginia.
24/7 Wall St.'s 12-month price target for RDNT is $84.71, rated Buy. The Wall Street consensus target is $94.62. RDNT price prediction →